Trabedersen to target transforming growth factor-beta: when the journey is not the reward, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132-142)

Comment

Wolfgang Wick et al. Neuro Oncol. 2011 May.

. 2011 May;13(5):559-60; author reply 561-2.

doi: 10.1093/neuonc/nor046.

No abstract available

Comment on

Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study.
Bogdahn U, Hau P, Stockhammer G, Venkataramana NK, Mahapatra AK, Suri A, Balasubramaniam A, Nair S, Oliushine V, Parfenov V, Poverennova I, Zaaroor M, Jachimczak P, Ludwig S, Schmaus S, Heinrichs H, Schlingensiepen KH; Trabedersen Glioma Study Group. Bogdahn U, et al. Neuro Oncol. 2011 Jan;13(1):132-42. doi: 10.1093/neuonc/noq142. Epub 2010 Oct 27. Neuro Oncol. 2011. PMID: 20980335 Free PMC article. Clinical Trial.

1. Bogdahn U, Hau P, Stockhammer G, et al. Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol. 2011;13:132–142. - PMC - PubMed
1. Wick W, Naumann U, Weller M. Transforming growth factor-β: a molecular target for the future therapy of glioblastoma. Curr Pharm Design. 2006;12:341–349. - PubMed
1. Weller M, Fontana A. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-β, T cell apoptosis, and the immune privilege of the brain. Brain Res Rev. 1995;21:128–151. - PubMed
1. Wick W, Grimmel C, Wild-Bode C, et al. Ezrin-dependent promotion of glioma cell clonogenicity, motility and invasion mediated by BCL-2 and TGF-β2. J Neurosci. 2001;21:3360–3368. - PMC - PubMed
1. Friese MA, Wischhusen J, Wick W, et al. RNA interference targeting TGF-β1,2 enhances NKG2D-mediated anti-glioma immune response, inhibits glioma cell migration and invasiveness and abrogates tumorigenicity in vivo. Cancer Res. 2004;64:7596–7603. - PubMed